Adenovirus-mediated transfer of a p53 gene in ovarian cancer.
Given the lack of effective conventional therapy, those patients with recurrent or refractory ovarian cancer should be considered for currently approved investigational gene therapy protocols. Several studies have shown a potential modality of p53 gene transfer in cancer gene therapy. We also developed a new recombinant adenovirus carrying a wild-type p53 gene (AxCAp53). Although the efficacy of AxCAp53 to suppression of cell growth was not sufficient, AxCAp53 increased sensitivity to CDDP in ovarian cancer cells with deletion of the p53 gene. The combination of CDDP and AxCAp53 may be a potential strategy for the therapy of CDDP resistant ovarian cancer.
Kigawa
J
J
Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan.
Terakawa
N
N
D000260:Adenoviruses, Human; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D018014:Gene Transfer Techniques; D016158:Genes, p53; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000628:therapy*
D000970:Antineoplastic Agents; D002945:Cisplatin